source
- FDA holds Type A meeting with Atara after CRL issued for tabelecleucel in EBV-positive PTLDThe FDA and Atara Biotherapeutics met in a Type A meeting to discuss the complete response letter (CRL) that the agency issued for the biologics license application of tabelecleucel, a therapy for…
- Clinicians map next-line EGFR lung cancer treatments using NGS, radiation, chemo, amivantamab and ADCsClinicians treating non‑small cell lung cancer with EGFR mutations must adapt when tumors become resistant to first‑line therapies. The latest guidance highlights the use of next‑generation sequenc…